FY2024 EPS Estimates for Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Increased by Analyst

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) – Research analysts at Capital One Financial increased their FY2024 earnings per share estimates for Amphastar Pharmaceuticals in a research report issued on Wednesday, April 17th. Capital One Financial analyst T. Chiang now expects that the company will post earnings of $3.48 per share for the year, up from their previous estimate of $3.43. The consensus estimate for Amphastar Pharmaceuticals’ current full-year earnings is $3.42 per share.

Several other research analysts have also commented on AMPH. JPMorgan Chase & Co. assumed coverage on Amphastar Pharmaceuticals in a research report on Tuesday, March 5th. They issued an “overweight” rating and a $60.00 price target for the company. Needham & Company LLC reiterated a “hold” rating on shares of Amphastar Pharmaceuticals in a research report on Wednesday, April 10th. Finally, StockNews.com lowered Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, February 29th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, Amphastar Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $66.00.

Amphastar Pharmaceuticals Trading Down 3.5 %

AMPH opened at $38.65 on Friday. The firm has a market cap of $1.89 billion, a P/E ratio of 14.98, a P/E/G ratio of 0.96 and a beta of 0.84. Amphastar Pharmaceuticals has a 12 month low of $35.62 and a 12 month high of $67.66. The company has a current ratio of 2.17, a quick ratio of 1.70 and a debt-to-equity ratio of 0.92. The stock has a 50-day moving average of $46.59 and a 200 day moving average of $51.23.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its earnings results on Wednesday, February 28th. The company reported $0.81 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.84 by ($0.03). Amphastar Pharmaceuticals had a return on equity of 26.95% and a net margin of 21.34%. The firm had revenue of $178.11 million during the quarter, compared to the consensus estimate of $174.90 million.

Insider Buying and Selling at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, Director Michael A. Zasloff sold 12,500 shares of the business’s stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $47.18, for a total transaction of $589,750.00. Following the completion of the transaction, the director now owns 21,326 shares in the company, valued at $1,006,160.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Amphastar Pharmaceuticals news, Director Floyd F. Petersen sold 500 shares of the business’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $53.10, for a total transaction of $26,550.00. Following the completion of the transaction, the director now owns 80,333 shares in the company, valued at $4,265,682.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Michael A. Zasloff sold 12,500 shares of the business’s stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $47.18, for a total value of $589,750.00. Following the transaction, the director now owns 21,326 shares of the company’s stock, valued at approximately $1,006,160.68. The disclosure for this sale can be found here. Insiders sold 14,000 shares of company stock worth $660,860 over the last 90 days. Company insiders own 28.40% of the company’s stock.

Institutional Trading of Amphastar Pharmaceuticals

A number of large investors have recently modified their holdings of the company. Exchange Traded Concepts LLC boosted its holdings in shares of Amphastar Pharmaceuticals by 0.8% in the fourth quarter. Exchange Traded Concepts LLC now owns 21,440 shares of the company’s stock valued at $1,326,000 after purchasing an additional 169 shares during the period. Quadrant Capital Group LLC raised its stake in Amphastar Pharmaceuticals by 27.8% in the fourth quarter. Quadrant Capital Group LLC now owns 1,026 shares of the company’s stock worth $63,000 after buying an additional 223 shares in the last quarter. Guidance Capital Inc. raised its stake in Amphastar Pharmaceuticals by 3.9% in the third quarter. Guidance Capital Inc. now owns 7,152 shares of the company’s stock worth $321,000 after buying an additional 267 shares in the last quarter. Bridge City Capital LLC raised its stake in Amphastar Pharmaceuticals by 0.8% in the first quarter. Bridge City Capital LLC now owns 34,773 shares of the company’s stock worth $1,527,000 after buying an additional 275 shares in the last quarter. Finally, Los Angeles Capital Management LLC raised its stake in Amphastar Pharmaceuticals by 1.3% in the third quarter. Los Angeles Capital Management LLC now owns 27,443 shares of the company’s stock worth $1,262,000 after buying an additional 358 shares in the last quarter. Hedge funds and other institutional investors own 65.09% of the company’s stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.